This is a prospective, multicenter, randomized controlled study aimed at evaluating the efficacy and safety of Trop2-ADC monotherapy or immune combination strategy in the treatment of advanced triple-negative breast cancer.
1) adult female patients (aged 18-70 years) with metastatic triple negative breast cancer confirmed by pathology or imaging;
2) no more than two previous lines of therapy for metastatic disease;
3) ECOG performance status ≤2 and expected survival time ≥ 3 months;
4) At least one measurable lesion on imaging within 2 weeks before enrollment; Or simple bone metastases;
1) patients with a known allergy to the active ingredient or other ingredient of the study drug.
2) patients with known resistance to trop2-ADC drugs. 、
3) receiving radiotherapy, chemotherapy, or endocrine therapy within 4 weeks before enrollment, or participating in any interventional drug clinical trial;
4) pregnant or lactating women or women of childbearing age who refused to use effective contraception during the study period.